Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials

Galapagos has entered a collaboration with Gilead on Gamgertamig, unlocking $500 million in cash and aiming for 2027 registrational trials.

• Galapagos announced a partnership with Gilead around gamgertamig
• The deal unlocks $500M in cash for Galapagos
• The companies are targeting registrational trials starting in 2027
• The news is most relevant for GLPG valuation and biotech partnership sentiment rather than the broader market